体外血液净化技术对脓毒症临床预后及细胞因子影响的Meta分析

doi:10.3969/j.issn.1004-583X.2022.01.001

摘要/Abstract

摘要：

目的系统评价体外血液净化技术(extracorporeal hemopurification, EH)对脓毒症患者临床预后的影响,并探讨相关细胞因子水平变化与临床预后的关联。方法检索Pubmed, Web of Science, Cochrane Library, 中国知网数据库,纳入从2010年1月至2020年1月所有符合标准的,有关EH对脓毒症患者影响的相关文献,使用Review Manager 5.3进行森林图分析,探讨EH与脓毒症患者的住院病死率(in-hospital mortality, IHM)和重症监护室住院时长的关联,并进一步分析细胞因子水平的改变与临床预后关联。结果共28篇文献纳入研究,累计2 587例患者,Meta分析结果显示EH(血液灌注、血液滤过、血液吸附、细胞因子吸附等)可显著降低脓毒症患者的IHM(OR=0.83, P=0.04),但并不影响患者的重症监护室住院时长(OR=-0.50, P=0.69)。亚组分析提示:高容量血液滤过或多黏菌素B血液灌注,并不能降低脓毒症患者的IHM(P=0.22;P=0.87);同样EH不能改善烧伤性脓毒症以及脓毒症性急性肾衰竭患者的IHM(P=0.08;P=0.77)。针对EH带来相关细胞因子水平降低的脓毒症患者,虽然IHM没有显著下降(P=0.48), 但是重症监护室的住院时长明显缩短(OR=-17.58,P=0.04)。结论脓毒症患者,若无相关禁忌证,建议行体外血液净化作为辅助治疗。在治疗过程中,对相关细胞因子水平的调控,是有效缩短重症监护室住院时长的关键。

关键词: 脓毒症, 体外血液净化技术, 细胞因子水平, 重症监护室住院时长

Abstract:

Objective The purpose of this study is to systematically analyze the effect of extracorporeal hemopurification (EH) for clinical prognosis, and the association between EH-related cytokines levels and clinical prognosis for septic patients. Methods Available studies accessing the effect of extracorporeal hemopurification for septic patients were collected from Pubmed, Web of Science, Cochrane Library and China National Knowledge Internet between January 2010 and January 2020. Relationships between EH and in-hospital mortality (IHM) and length of intensive care unit in sepsis patients were calculated and systematically analyzed by Forest Plot in Review Manager 5.3. We further analyzed the correlation between changing of cytokine levels and clinical prognosis. Results Twenty-eight researches which covered a total of 2587 patients were included in this meta-analysis. The results indicated that EH (hemoperfusion, hemofiltration, hemoadsorption, cytosorb, et. al) could significantly decrease IHM (OR=0.83, P=0.04) without affecting the length of intensive care unit (OR=-0.50, P=0.69). Subgroup analysis suggested that High-volume Hemofltration or Hemoperfusion with Polymyxin B-immobilized cartridge failed to improve IHM (P=0.22; P=0.87); meanwhile, EH showed little therapy efficiency in severe burn septic patients or septic patients with acute kidney injury (P=0.08; P=0.77). During the whole EH period, septic patients with lower cytokine levels at last presented no benefit for a lower risk of IHM (P=0.48), but the length of intensive care unit was significantly decreased (OR=-17.58, P=0.04). Conclusion Routine EH is recommended for septic patients with no contraindication. Controlling relative levels of cytokines during the whole treatment is a useful way to shorten the length of intensive care unit.

Key words: sepsis, extracorporeal hemopurification, cytokine level, length of intensive care unit

中图分类号:

R631

肖刘牛, 钟燕霞, 李树生. 体外血液净化技术对脓毒症临床预后及细胞因子影响的Meta分析[J]. 临床荟萃, 2022, 37(1): 5-13.

Xiao Liuniu, Zhong Yanxia, Li Shusheng. Effect of extracorporeal hemopurification for clinical prognosis and cytokine levels of septic: A meta-analysis[J]. Clinical Focus, 2022, 37(1): 5-13.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.01.001

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I1/5

图/表 12

参考文献 35

[1]	Rimmele T, Kellum JA. Clinical review: Blood purification for sepsis[J]. Critical Care, 2011, 15(1):205. doi: 10.1186/cc9411 URL
[2]	Putzu A, Schorer R, Lopez-Delgado JC, et al. Blood purification and mortality in sepsis and septic shock[J]. Anesthesiology, 2019, 131(3):580-593. doi: 10.1097/ALN.0000000000002820 URL
[3]	Zhou F, Peng Z, Murugan R, et al. Blood purification and mortality in sepsis[J]. Crit Care Med, 2013, 41(9):2209-2220. doi: 10.1097/CCM.0b013e31828cf412 URL
[4]	Steltzer H, Grieb A, Mostafa K, et al. Use of Cytosorb in traumatic amputation of the forearm and severe septic shock[J]. Case Rep Crit Care, 2017, 2017:8747616.
[5]	Kade G, Literacki S, Rzeszotarska A, et al. Removal of procalcitonin and selected cytokines during continuous veno-venous hemodialysis using high cutoff hemofilters in patients with sepsis and acute kidney injury[J]. Blood Purif, 2018, 46(2):153-159. doi: 10.1159/000488929 URL
[6]	Chihara S, Masuda Y, Tatsumi H, et al. Evaluation of pre-and post-dilution continuous veno-venous hemofiltration on leukocyte and platelet function in patients with sepsis[J]. Int J Artif Organs, 2019, 42(1):9-16. doi: 10.1177/0391398818801292 pmid: 30278811
[7]	Oudemans-Van Straaten HM, Elbers PW. How to explain and exploit the beneficial effects of high-volume hemofiltration on hemodynamics and strong ion gap[J]. Intensive Care Med, 2013, 39(6):1140-1142. doi: 10.1007/s00134-013-2820-4 pmid: 23361626
[8]	Hassan J, Cader RA, Kong NC, et al. Original article: Coupled plasma filtration adsorption (CPFA) plus continuous veno-venous haemofiltration (CVVH) versus CVVH alone as an adjunctive therapy in the treatment of sepsis[J]. EXCLI J, 2013, 12:681-692. pmid: 26600735
[9]	Maynar J, Martínez-Sagasti F, Herrera-Gutiérrez M, et al. Direct hemoperfusion with polymyxin B-immobilized cartridge in severe sepsis due to intestinal perforation: hemodynamic findings and clinical considerations in anticoagulation therapy[J]. Rev Esp Quimioter, 2013, 26(2):151-158.
[10]	Quenot JP, Binquet C, Vinsonneau C, et al. Very high volume hemofiltration with the Cascade system in septic shock patients[J]. Intensive Care Med, 2015, 41(12):2111-2120. doi: 10.1007/s00134-015-4056-y URL
[11]	Quinto BM, Iizuka IJ, Monte JC, et al. TNF-α depuration is a predictor of mortality in critically ill patients under continuous veno-venous hemodiafiltration treatment[J]. Cytokine, 2015, 71(2):255-260. doi: 10.1016/j.cyto.2014.10.024 pmid: 25461406
[12]	Schädler D, Pausch C, Heise D, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial[J]. PLoS One, 2017, 12(10):e187015.
[13]	Guo J, Tao W, Tang D, et al. Th17/Regulatory T cell imbalance in sepsis patients with multiple organ dysfunction syndrome: Attenuated by high-volume hemofiltration[J]. Int J Artif Organs, 2017, 40(11):607-614. doi: 10.5301/ijao.5000625 URL
[14]	Huang Z, Wang SR, Su W, et al. Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column[J]. Ther Apher Dial, 2010, 14(6):596-602. doi: 10.1111/tap.2010.14.issue-6 URL
[15]	Kim JJ, Park YJ, Moon KY, et al. Polymyxin B hemoperfusion as a feasible therapy after source control in abdominal septic shock[J]. World J Gastrointest Surg, 2019, 11(12):422-432. doi: 10.4240/wjgs.v11.i12.422 URL
[16]	Friesecke S, Träger K, Schittek GA, et al. International registry on the use of the CytoSorb^® adsorber in ICU patients: Study protocol and preliminary results[J]. Med Klin Intensivmed Notfmed, 2019, 114(8):699-707. doi: 10.1007/s00063-017-0342-5 pmid: 28871441
[17]	Servillo G, Vargas M, Pastore A, et al. Immunomodulatory effect of continuous venovenous hemofiltration during sepsis: Preliminary data[J]. Biomed Res Int, 2013, 2013:108951.
[18]	Joannes-Boyau O, Honoré PM, Perez P, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): A multicentre randomized controlled trial[J]. Intensive Care Med, 2013, 39(9):1535-1546. doi: 10.1007/s00134-013-2967-z pmid: 23740278
[19]	Chung KK, Coates EC, Smith DJ Jr, et al. High-volume hemofiltration in adult burn patients with septic shock and acute kidney injury: A multicenter randomized controlled trial[J]. Crit Care, 2017, 21(1):89. doi: 10.1186/s13054-017-1678-1 URL
[20]	Park JT, Lee H, Kee YK, et al. High-dose versus conventional-dose continuous venovenous hemodiafiltration and patient and kidney survival and cytokine removal in sepsis-associated acute kidney injury: A randomized controlled trial[J]. Am J Kidney Dis, 2016, 68(4):599-608. doi: 10.1053/j.ajkd.2016.02.049 URL
[21]	Friesecke S, Stecher SS, Gross S, et al. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: A prospective single-center study[J]. J Artif Organs, 2017, 20(3):252-259. doi: 10.1007/s10047-017-0967-4 pmid: 28589286
[22]	Hawchar F, László I, Öveges N, et al. Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study[J]. J Crit Care, 2019, 49:172-178. doi: S0883-9441(18)30777-9 pmid: 30448517
[23]	Xu C, Fan K, Xie L, et al. Evaluation of optimized continuous venovenous hemodiafiltration therapy efficiency in severe burn patients with sepsis[J]. Burns Trauma, 2014, 2(3):125-129. doi: 10.4103/2321-3868.137604 URL
[24]	Livigni S, Bertolini G, Rossi C, et al. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: A multicenter randomised controlled clinical trial[J]. BMJ Open, 2014, 4(1):e003536.
[25]	Tamme K, Maddison L, Kruusat R, et al. Effects of high volume haemodiafiltration on inflammatory response profile and microcirculation in patients with septic shock[J]. Biomed Res Int, 2015, 2015:125615.
[26]	Wu J, Ren J, Liu Q, et al. Effects of changes in the levels of damage-associated molecular patterns following continuous veno-venous hemofiltration therapy on outcomes in acute kidney injury patients with sepsis[J]. Front Immunol, 2019, 9:3052. doi: 10.3389/fimmu.2018.03052 URL
[27]	Kade G, Lubas A, Rzeszotarska A, et al. Effectiveness of high cut-off hemofilters in the removal of selected cytokines in patients during septic shock accompanied by acute kidney injury-preliminary study[J]. Med Sci Monit, 2016, 22:4338-4344. doi: 10.12659/MSM.896819 URL
[28]	Zhang P, Yang Y, Lv R, et al. Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: A single-center randomized clinical trial[J]. Nephrol Dial Transplant, 2012, 27(3):967-973. doi: 10.1093/ndt/gfr486 URL
[29]	Dellinger RP, Bagshaw SM, Antonelli M, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level[J]. JAMA, 2018, 320(14):1455-1463. doi: 10.1001/jama.2018.14618 pmid: 30304428
[30]	Payen DM, Guilhot J, Launey Y, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: A multicenter randomized control trial[J]. Intensive Care Med, 2015, 41(6):975-984. doi: 10.1007/s00134-015-3751-z URL
[31]	You B, Zhang YL, Luo GX, et al. Early application of continuous high-volume haemofiltration can reduce sepsis and improve the prognosis of patients with severe burns[J]. Crit Care, 2018, 22(1):173. doi: 10.1186/s13054-018-2095-9 URL
[32]	Miao H, Wang F, Xiong X, et al. Clinical benefits of high-volume hemofiltration in critically Ill pediatric patients with severe sepsis: A retrospective cohort study[J]. Blood Purif, 2018, 45(1-3):18-27. doi: 10.1159/000481249 URL
[33]	Zuccari S, Damiani E, Domizi R, et al. Changes in cytokines, haemodynamics and microcirculation in patients with sepsis/septic shock undergoing continuous renal replacement therapy and blood purification with cytosorb[J]. Blood Purif, 2020, 49(1-2):107-113. doi: 10.1159/000502540 URL
[34]	Shum HP, Leung YW, Lam SM, et al. Alteco endotoxin hemoadsorption in gram-negative septic shock patients[J]. Indian J Crit Care Med, 2014, 18(12):783-788. doi: 10.4103/0972-5229.146305 URL
[35]	Peng ZY, Wang HZ, Carter MJ, et al. Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis[J]. Kidney Int, 2012, 81(4):363-369. doi: 10.1038/ki.2011.320 URL